CeriBell (CBLL) Competitors

$16.30 -0.16 (-0.97%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$16.32 +0.02 (+0.09%)

As of 05/15/2026 04:10 PM Eastern

CBLL vs. LMAT, TMDX, AXGN, NVCR, and ESTA

Should you buy CeriBell stock or one of its competitors? MarketBeat compares CeriBell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CeriBell include LeMaitre Vascular (LMAT), TransMedics Group (TMDX), AxoGen (AXGN), NovoCure (NVCR), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.

How does CeriBell compare to LeMaitre Vascular?

CeriBell (NASDAQ:CBLL) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

84.6% of LeMaitre Vascular shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

LeMaitre Vascular has a net margin of 24.35% compared to CeriBell's net margin of -63.51%. LeMaitre Vascular's return on equity of 15.36% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
LeMaitre Vascular	24.35%	15.36%	9.78%

CeriBell has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 36.20%. LeMaitre Vascular has a consensus target price of $112.60, indicating a potential upside of 15.71%. Given CeriBell's stronger consensus rating and higher possible upside, equities analysts clearly believe CeriBell is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

LeMaitre Vascular has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	6.94	-$53.41M	-$1.63	N/A
LeMaitre Vascular	$249.60M	8.91	$57.73M	$2.71	35.91

In the previous week, LeMaitre Vascular had 3 more articles in the media than CeriBell. MarketBeat recorded 12 mentions for LeMaitre Vascular and 9 mentions for CeriBell. CeriBell's average media sentiment score of 0.44 beat LeMaitre Vascular's score of 0.25 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LeMaitre Vascular beats CeriBell on 10 of the 15 factors compared between the two stocks.

How does CeriBell compare to TransMedics Group?

CeriBell (NASDAQ:CBLL) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	6.94	-$53.41M	-$1.63	N/A
TransMedics Group	$605.49M	3.61	$190.29M	$4.40	14.36

In the previous week, CeriBell had 5 more articles in the media than TransMedics Group. MarketBeat recorded 9 mentions for CeriBell and 4 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.45 beat CeriBell's score of 0.44 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 36.20%. TransMedics Group has a consensus target price of $135.00, indicating a potential upside of 113.61%. Given TransMedics Group's higher probable upside, analysts clearly believe TransMedics Group is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
TransMedics Group	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

CeriBell has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

TransMedics Group has a net margin of 27.04% compared to CeriBell's net margin of -63.51%. TransMedics Group's return on equity of 22.38% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
TransMedics Group	27.04%	22.38%	8.46%

99.7% of TransMedics Group shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

TransMedics Group beats CeriBell on 12 of the 17 factors compared between the two stocks.

How does CeriBell compare to AxoGen?

AxoGen (NASDAQ:AXGN) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.68	-$15.70M	-$0.64	N/A
CeriBell	$89.06M	6.94	-$53.41M	-$1.63	N/A

In the previous week, AxoGen had 3 more articles in the media than CeriBell. MarketBeat recorded 12 mentions for AxoGen and 9 mentions for CeriBell. AxoGen's average media sentiment score of 0.72 beat CeriBell's score of 0.44 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen presently has a consensus target price of $46.50, indicating a potential upside of 13.44%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 36.20%. Given CeriBell's stronger consensus rating and higher possible upside, analysts plainly believe CeriBell is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

AxoGen has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

AxoGen has a net margin of -13.21% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -9.63% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
CeriBell	-63.51%	-38.19%	-30.92%

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

AxoGen beats CeriBell on 12 of the 17 factors compared between the two stocks.

How does CeriBell compare to NovoCure?

NovoCure (NASDAQ:NVCR) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

CeriBell has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.11	-$136.23M	-$1.53	N/A
CeriBell	$89.06M	6.94	-$53.41M	-$1.63	N/A

In the previous week, CeriBell had 7 more articles in the media than NovoCure. MarketBeat recorded 9 mentions for CeriBell and 2 mentions for NovoCure. NovoCure's average media sentiment score of 1.67 beat CeriBell's score of 0.44 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.6% of NovoCure shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NovoCure has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

NovoCure presently has a consensus target price of $27.29, indicating a potential upside of 55.21%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 36.20%. Given NovoCure's higher possible upside, equities research analysts clearly believe NovoCure is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

NovoCure has a net margin of -25.66% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
CeriBell	-63.51%	-38.19%	-30.92%

Summary

CeriBell beats NovoCure on 9 of the 16 factors compared between the two stocks.

How does CeriBell compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

In the previous week, CeriBell had 7 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for CeriBell and 2 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.66 beat CeriBell's score of 0.44 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs presently has a consensus target price of $87.14, indicating a potential upside of 32.52%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 36.20%. Given CeriBell's stronger consensus rating and higher possible upside, analysts clearly believe CeriBell is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Establishment Labs has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

Establishment Labs has a net margin of -19.05% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
CeriBell	-63.51%	-38.19%	-30.92%

Establishment Labs has higher revenue and earnings than CeriBell. Establishment Labs is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.17	-$51.06M	-$1.49	N/A
CeriBell	$89.06M	6.94	-$53.41M	-$1.63	N/A

Summary

Establishment Labs beats CeriBell on 10 of the 17 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$624.54M	$8.15B	$6.33B	$12.47B
Dividend Yield	N/A	2.51%	2.80%	5.28%
P/E Ratio	-10.00	15.81	20.29	25.24
Price / Sales	6.94	8.02	547.55	78.31
Price / Cash	N/A	16.89	43.04	56.04
Price / Book	4.39	3.78	9.83	6.91
Net Income	-$53.41M	$223.05M	$3.56B	$334.11M
7 Day Performance	-19.31%	-3.51%	0.26%	0.01%
1 Month Performance	-21.41%	-0.61%	-1.30%	1.17%
1 Year Performance	-9.29%	-0.20%	33.62%	30.68%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	2.4699 of 5 stars	$16.30 -1.0%	$22.20 +36.2%	-7.3%	$624.54M	$89.06M	N/A	N/A	Earnings Report Analyst Forecast
LMAT LeMaitre Vascular	4.5145 of 5 stars	$99.04 -2.6%	$112.60 +13.7%	+16.8%	$2.26B	$249.60M	36.57	490
TMDX TransMedics Group	4.2454 of 5 stars	$64.33 +0.0%	$135.00 +109.9%	-48.1%	$2.24B	$605.49M	14.74	210
AXGN AxoGen	3.463 of 5 stars	$41.38 +1.4%	$46.50 +12.4%	+248.0%	$2.19B	$225.21M	N/A	450
NVCR NovoCure	3.6746 of 5 stars	$18.40 +1.7%	$27.29 +48.3%	-0.1%	$2.13B	$655.35M	N/A	1,605

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. LMAT, TMDX, AXGN, NVCR, and ESTA

How does CeriBell compare to LeMaitre Vascular?

Summary

How does CeriBell compare to TransMedics Group?

Summary

How does CeriBell compare to AxoGen?

Summary

How does CeriBell compare to NovoCure?

Summary

How does CeriBell compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. LMAT, TMDX, AXGN, NVCR, and ESTA

How does CeriBell compare to LeMaitre Vascular?

Do institutionals & insiders have more ownership in CBLL or LMAT?

Is CBLL or LMAT more profitable?

Which has more volatility & risk, CBLL or LMAT?

Do analysts recommend CBLL or LMAT?

Which has preferable earnings and valuation, CBLL or LMAT?

Does the media prefer CBLL or LMAT?

Summary

How does CeriBell compare to TransMedics Group?

Which has better earnings and valuation, CBLL or TMDX?

Does the media prefer CBLL or TMDX?

Do analysts rate CBLL or TMDX?

Which has more risk and volatility, CBLL or TMDX?

Is CBLL or TMDX more profitable?

Do institutionals & insiders believe in CBLL or TMDX?

Summary

How does CeriBell compare to AxoGen?

Which has stronger earnings and valuation, AXGN or CBLL?

Does the media favor AXGN or CBLL?

Do analysts recommend AXGN or CBLL?

Which has more risk and volatility, AXGN or CBLL?

Is AXGN or CBLL more profitable?

Do institutionals and insiders have more ownership in AXGN or CBLL?

Summary

How does CeriBell compare to NovoCure?

Which has higher valuation & earnings, NVCR or CBLL?

Does the media refer more to NVCR or CBLL?

Do institutionals and insiders have more ownership in NVCR or CBLL?

Which has more volatility & risk, NVCR or CBLL?

Do analysts prefer NVCR or CBLL?

Is NVCR or CBLL more profitable?

Summary

How does CeriBell compare to Establishment Labs?

Does the media refer more to ESTA or CBLL?

Do analysts prefer ESTA or CBLL?

Do institutionals and insiders have more ownership in ESTA or CBLL?

Which has more volatility & risk, ESTA or CBLL?

Is ESTA or CBLL more profitable?

Which has higher valuation & earnings, ESTA or CBLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools